Introduction
Currently, more than 60 million people have been infected with human immunodeficiency virus type 1 (HIV-1). 1 Over 5 million new HIV-1 infections occurred in 2002, and acquired immunodeficiency syndrome (AIDS) is spreading rapidly. 2 These facts highlight the need for a prophylactic vaccine against HIV-1. The various HIV-1 subtypes have biological and antigenic differences. 3 Whether an HIV-1 vaccine needs to comprise different subtype antigens is a matter for debate, but most investigators agree that broadly crossreactive antibodies and cellular immune responses are desirable. 4, 5 A recombinant HIV-1 envelope protein (rgp120) was used in the world's first phase III HIV vaccine trial resulting in the induction of immunity, but unfortunately without conferring substantial protection. 6 New strategies for HIV-1 vaccination include attenuated vaccinia virus carrying HIV gene segments, 7 recombinant adenovirus vectors 8 and plasmids encoding HIV-1 proteins or peptides. 7, 9, 10 DNA vaccination is especially suitable since it preferably induces cellular immunity, an important host response against intracellular microbes. DNA immunogens can easily be constructed to express antigens from multiple HIV-1 antigens and/or subtypes. [11] [12] [13] Since immune responses to plasmid-encoded antigens tend to be weak in primates, numerous strategies for enhancing DNA immunization have been evaluated. Cytokines or cytokine genes have been shown to be potent immune enhancers in genetic immunization. For example, seven out of eight macaques immunized with a gene encoding HIV-1 gag together with a fusion protein of interleukin-2 and immunoglobulin (IL-2/Ig) survived challenge with the pathogenic chimeric simianhuman immunodeficiency virus (SHIV 89.6P). 14, 15 Immunization with a bicistronic plasmid that coexpresses HIV-1 gp120 and granulocyte-macrophage colony-stimulating factor (GM-CSF) under the control of a single promoter led to a dramatic augmentation of vaccineelicited CD4 þ T-cell responses, but did not affect either antibody or CD8 þ T-cell responses in mice. 16 Coinjection of the IL-12, IL-7 and GM-CSF genes with the antigen gene has been used to enhance genetic immunization in mice. [17] [18] [19] [20] [21] Furthermore, the HIV coreceptor gene CCR5 has been used together with recombinant GM-CSF (rGM-CSF) to induce immune responses against CCR5 in macaques. 22 Protein subunit vaccines, enhanced by naturally hypomethylated bacterial DNA in a specific nucleotide context (5 0 -Pu-Pu-CpG-Pyr-Pyr-3 0 ) can stimulate both arms of the immune system. 23 Protein together with synthetic immunostimulatory CpG oligonucleotides (CpG-ODN) has been used to activate responses to, for example, the HIV-1 envelope and reverse transcriptase proteins in mice 24, 25 and the hepatitis B surface antigen in mice and man.
Here, we describe immunization with HIV-1 gp160 DNA alone, typically resulting in poor humoral immunity. A single injection of gp160 DNA was given with recombinant GM-CSF, resulting in potent antibody induction. Finally, we performed a prime-boost immunization protocol by priming with gp160 DNA together with rGM-CSF and then boosting with rgp160 protein.
Particularly, the priming with HIV-1 gp160 DNA together with recombinant GM-CSF induces high titers of broadly neutralizing antibodies. The HIV neutralization was even broader if the envelope DNA immunogen derived from multiple viral subtypes.
Results

Antibody induction
Immunizations with DNA plasmids expressing the HIV-1 gp160 gene of subtypes A, B or C without any adjuvant did not result in detectable antibodies (0/40 animals), but did give HIV-specific induction of cellular immunity (Table 1 , part I). Envelope DNA immunizations together with rGM-CSF resulted in anti-gp160 antibody titers of 1.5 Â 10 4 , at 30 days after a single immunization (Table 1 , part II). In a third set of immunizations, priming twice with gp160 genes together with rGM-CSF induced strong antibody responses in all multi-subtype-immunized mice, with a group geometric mean anti-gp160 IgG titer of 2 Â 10 5 (Table 1 , part III and Figure 1 ). After booster immunization with rgp160 and CpG-ODN, animals in the multi-subtype DNA-immunized group retained high antibody responses, with a geometric mean group titer of 4 Â 10 5 , at 14 days after immunization (Figure 1a) . Subtype B DNA-primed animals showed lower antibody response frequencies than the multi-subtype DNAimmunized mice, with altogether eight out of 12 mice responding with ELISA antibodies 14 days after the second DNA priming (Figure 1a ). This was also reflected in the two groups' mean anti-gp160 IgG titers of approximately 3 Â 10 3 and 2 Â 10 2 , respectively. Antibody titers were augmented approximately one logarithm after protein boosting. The mice receiving rgp160 protein with CpG-ODN (the B1 group) reached a mean titer of 2 Â 10 4 ; animals given rgp160 protein alone (the B2 group) showed a mean titer of 3 Â 10 3 . The IgG1/IgG2a isotype ratios for responding animals were determined (Figure 1b) . All groups had a T-helper 2 (Th2) type of response with predominant IgG1 anti- Induction of broadly neutralizing HIV-1 antibodies E Rollman et al bodies before boost (mean group ratios ranging from 9 to 19). In animals that received CpG-ODN in the booster immunization (the ABC and B1 groups), this profile changed in favor of a more balanced Th2/Th1-like profile, with ratios of 4 and 5, respectively. Animals boosted with rgp160 without CpG-ODN (the B2 group) kept their prominent Th2-like profile, with a mean IgG1/ IgG2a ratio of 13. IgG1 levels were augmented two-to three-fold and IgG2a levels increased two-to 15-fold postboost in the two groups that received CpG-ODN.
IgG2a responses remained low in the group boosted with rgp160 only (data not shown).
Overlapping peptides covering the subtype B gp120 antigen were used to screen for vaccine-induced humoral responses to antigenic determinants ( Figure 2 ). The peptides corresponded to the gp120 constant regions 2 to 5 (C2-5) and variable regions 3 to 5 (V3-5). 28 We show that multi-subtype immunization with HIV-1 gp160 genes of subtypes A, B and C together with rGM-CSF results in the serum IgG recognition of four major gp120 sites (V3, C3, V4 and V5). The serum IgG from ABC DNA primed animals recognized 65% of all peptides in the constant and variable regions (Figure 2a ). Boosting the same animals with rgp160 together with CpG-ODN increased the antibody epitope recognition of C2, C3, C4 and C5, with an overall peptide recognition frequency of 73%. Immunization with subtype B DNA resulted in the recognition of epitope regions in C2, C3, C4 and V5 with peptide recognition frequencies of 29% (group B1) and 23% (group B2). Boosting the subtype B DNA-immunized animals with rgp160, with or without CpG-ODN, increased the response to epitopes in the V3 and C3 region (Figure 2b and c). The sera from DNA-primed animals recognized the gp41 peptides NEQLLELDK-WASLWN (optical density (OD) 0.870.1) and KDQQLLGIWGCSGKLICT (OD 1.770.3) to a similar extent (data not shown). The protein boost increased the IgG reactivity towards the two gp41 epitopes in all groups (OD 2.770.2 and 3.070.2, respectively).
Multi-subtype HIV-1 neutralization
The sera collected after one immunization with gp160 DNA and rGM-CSF (Table 1 , part II) had 90% neutralization capacity at serum dilutions of 1:10 against HIV-1 isolates IIIB and SF2 (data not shown). This is to be compared with the sera from the animals that received gp160 DNA without adjuvant, which resulted in the neutralization of approximately 30%. The sera from mice primed with DNA and rGMCSF (part III) responded with anti-gp160 antibodies with high potency to neutralize the subtype B HIV-1 strains LAI, SF-2 and 6920 already after DNA priming ( Table 2 ). The B1 group responded with similar neutralization titers to the subtype B viruses, whereas the B2 group had lower neutralization titers. The multi-subtype-immunized mice also neutralized the primary vaccine-matched subtypes A (92UG031) and C (92BR025) isolates ( Figure 3) . A 90% reduction of virus production was seen at 40-and 80-fold serum dilutions, respectively ( Table 2 ). The sera from animals immunized with subtype B DNA showed neutralization below 90% of subtypes A and C at the lowest (1:20) serum dilutions. Instead of raising the neutralizing capacity, the boost with recombinant protein reduced this, despite higher binding antibody titers ( Figure 3 ). The background neutralization was assessed in the sera from the untreated naïve mice. The background neutralization was generally very low ( Figure 3 , panels d, h and l).
Cellular immunity to multiple epitopes
Spleen T-cell proliferative responses (SI of [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] were seen in all (40/40) animals immunized with gp160 DNA without adjuvant (Table 1 , part I). Splenocytes from Induction of broadly neutralizing HIV-1 antibodies E Rollman et al Figure 3 Neutralization. Pooled sera from immunized mice were tested against the HIV-1 subtype A 92UG031 primary isolate (panels a-d), the subtype B LAI laboratory adapted strain (panels e-h) and the subtype C primary isolate 92BR025 (panels i-l). Solid lines represent the neutralization after two primes with gp160 encoding DNA and rGM-CSF; dashed lines represent the neutralization after boost with rgp160 with or without CpG-ODN. In the control panels (d, h and l), a solid line with filled circles represents the naïve control animals, the dashed line represents the subtype B V3-binding monoclonal P4/ D10 and the solid line represents HIVIG from Uganda, a broadly reactive polyclonal immunoglobulin.
Induction of broadly neutralizing HIV-1 antibodies E Rollman et al animals given a mixture of plasmids pKCMVgp160 A and C responded better (mean SI420) to rgp160 restimulation than splenocytes from animals that received one of the envelope genes (mean SI of 3-5). The same splenocytes were also stimulated with overlapping 15-mer peptides designed to match the gp120 V1-V5 region of subtypes A-and C-encoding plasmids. Again, animals immunized with plasmids pKCMVgp160 A and C together showed a higher degree of reactivity to A and C peptides than animals immunized with any of the single envelope genes ( Table 1 , part I). Immunization with rGM-CSF resulted in significantly increased T-cell proliferation against rgp160 in animals receiving the cytokine in comparison to animals that did not (Po0.05) ( Table 1 , part II). A distinct enhancement of IL-4 production (3276 pg/ml of IL-4) was also observed in the T-cell supernatants when splenocytes from animals given rGM-CSF were compared to those from animals given the DNA immunogen alone (471 pg/ml of IL-4).
All groups in part III showed T-cell proliferative responses after stimulation with rgp160 ( Figure 4a and summarized in Table 1 ). Restimulation with peptide pools matching subtypes A and C resulted in broadly reactive responses in animals primed with the multisubtype or subtype B DNA and later boosted by rgp160 with CpG-ODN (the ABC and B1 groups, Figure 4b ). Animals that received subtype B DNA followed by rgp160 without CpG-ODN were unable to recognize peptides representing subtypes A or C.
Pooled murine PBMC from each group were collected and analyzed for IFN-g production after stimulation with rgp160, at 6 weeks after the second prime with DNA and rGM-CSF ( Figure 5 ). Subtype B-immunized animals developed intermediate responses while ABC-immunized animals had weak IFN-g production. Splenocytes isolated 10 days after the booster immunization also produced IFN-g. The B1 group appeared to have the strongest CD8 þ reactivity as assessed by stimulation with rgp160. IFN-g responses were also detected in multi-subtype-immunized mice after the boost with rgp160 plus CpG-ODN. Only background levels were, however, seen in mice primed with subtype B DNA boosted with rgp160 without immunostimulatory ODNs (group B2).
Discussion
The induction of potent neutralizing anti-HIV antibody responses by any type of vaccination has proved difficult. 29, 30 We show that recombinant GM-CSF together with HIV-1 envelope genes from multiple subtypes (A, B and C) can change the envelope DNA immunogen into a potent entity that induces high titers of broadly reactive antibodies as well as cellular responses.
Plasmid-encoded GM-CSF has previously been used as a genetic adjuvant to DNA vaccination and has proved efficient in inducing both Th1-and Th2-type responses. 16, 20, 21, 31 The timing of the administration of the GM-CSF gene has been shown to be relevant for the type of immune response induced. When the GM-CSF gene was inoculated 3 days prior to genetic immunization, the immune response was mainly of the Th2 type, whereas simultaneous inoculation gave a balanced Th1/Th2 profile. Moreover, inoculation with the GM-CSF gene 3 days postimmunization gave a Th1 response. 32 As rGM-CSF protein was administered in our study at the time of immunization, we are likely to imitate the first of these scenarios, since the GM-CSF is present before antigen expression. Indeed, the addition of rGM-CSF to our DNA immunogen strongly favors antibody production with a Th2 tilted IgG subclass profile 33 and enhanced IL-4 production. The plasmids were able to induce general lymphocyte proliferation, as seen in the first two immunization protocols, with significantly increased proliferation when rGM-CSF was delivered together with the gp160 DNA.
The humoral immunity was enhanced by the combination of envelope genes from viruses of subtypes A, B and C. Multi-subtype DNA immunization contributed to a larger number of responders with higher antibody titers than immunization with subtype B DNA alone. Antibody epitope mapping of the gp120 revealed Figure 4 Lymphocyte proliferation. (a) Fresh splenocytes from individual mice were restimulated with rgp160 subtype B antigen followed by the detection of incorporated radiolabeled thymidine. The cutoff for response was determined to 27 000 cpm. Error bars indicate one standard deviation. (b) Frozen splenocytes were pooled and restimulated with subtype A-and C-specific overlapping peptides covering the gp120 V1-V5 region. The cutoff for response was determined to 1500 cpm. Error bars indicate the intra-assay standard deviation. Figure 5 Interferon-g ELISpot. Envelope-specific IFN-g-secreting cells were detected in pooled PBMC from each group isolated 6 weeks after DNA immunization (white bars) and in splenocytes 2 weeks after protein boost (gray boxes). The cutoff for a positive response was 50 SFCs per million cells (line).
Induction of broadly neutralizing HIV-1 antibodies
E Rollman et al broader antigen recognition in the sera obtained from multi-subtype-immunized animals in comparison to the sera from subtype B-immunized mice. The gp41 region in all DNA constructs was identical. By analyzing the IgG serum response towards two highly conserved gp41 regions, we show that the sera from the subtype B and the multi-subtype-immunized animals recognized the gp41 epitopes equally well. In addition, the multisubtype-immunized mice were able to neutralize primary isolates of subtypes A, B and C, whereas mice immunized with the gp160 gene derived from subtype B were not. We believe that the enhancement of antibody production, as well as the broader antibody specificity in the multi-subtype-immunized animals, are due to the presentation of multiple epitopes and thereby the stimulation of a broad clonal expansion of B cells. This is consistent with our previously reported finding that multi-subtype-immunized mice were more prone to develop antibody responses after experimental HIV challenge when compared to mice receiving the envelope gene from a single HIV-1 subtype. 29 Similarly, broad antibody responses have been reported in the clinic with multi-subtype infected individuals being capable of producing IgG that recognizes HIV from several subtypes. 34 Enhanced crossreactive T-cell proliferative responses were detected after immunization with a mixture of plasmids encoding subtype A and C proteins in comparison to inoculation with the individual plasmids. Combining plasmids encoding A, B and C antigens resulted in cellular immunity detected as gp160-specific IFN-g production of PBMCs.
The rgp160 protein boost resulted in a reduced neutralizing ability despite the induction of higher binding antibody titers and broader antigenic recognition. This may be explained by the fact that the rgp160 is most likely not present in its native trimeric form. Rather, it would consist of monomeric structures displaying nonneutralizing epitopes not shown on the native protein (reviewed in Poignard et al 35 ). Investigators have reported that gene-based immunogens may be more effective than protein antigens in inducing antibodies to conformational epitopes, 36 and that boosting with synthetic peptides may refocus the antibody response and can sometimes abrogate neutralizing capacity. 22 Similar mechanisms are most likely responsible for the postboost reduction of the neutralizing capacity in our study. After DNA priming, the subtype B-immunized animals (Figure 2, group B1) show an antibody response directed to the C3 region. This response was refocused towards the V3 region after the protein boost. In theory, these postboost V3-directed antibodies should be very potent in neutralizing the homologous LAI strain, but this was not the case in our study. The boost of V3 titers may not be sufficient to replace the neutralizing responses to conformational epitopes that were lost after the protein boost. Antibodies to conformational epitopes may be more relevant, but are difficult to detect using a standard peptide ELISA. We believe that the DNA immunogens are more efficient at presenting correctly folded epitopes. It is worth noting, however, that the neutralization of the LAI strain after the protein boost was still high.
The lymphocyte proliferation results, as measured by rgp160 B restimulation, were similar in all groups after protein boost. Priming with multi-subtype DNA followed by protein boosting together with CpG-ODN resulted in broad T cellular responses. In addition, the group primed with gp160 B DNA that received a protein boost with CpG-ODN (the B1 group) showed a higher degree of crossreactivity against subtypes A and C peptide pools compared to the group primed with gp160 B DNA followed by protein boost without CpG-ODN (the B2 group). Therefore, it could be argued that the CpG-ODN component helps in creating a Th milieu, likely to affect the overall cellular as well as humoral responses.
Cellular recall responses are known to be sensitive to antigen differences. The relatively low level of IFN-g detected in the ABC DNA primed and subtype B protein boosted animals could therefore be explained by the phenomenon of original antigenic sin at the cellular level. 37 More specifically, in HIV-1 infected patients therapeutically immunized with rgp160, it has been shown that boosting an already existing cellular immunity to the HIV-1 envelope must be carried out with a highly similar immunogen to evoke functional CTL. 38 Therefore, it is likely that only the subfraction of T cells responding to the subtype B antigen in the ABC group were able to produce IFN-g upon restimulation with the subtype B recombinant protein. Recombinant subtype A and C envelope proteins were unfortunately not commercially available at the time of this study.
The B2 group, boosted with rgp160 only, did not respond with IFN-g production above background levels, results that are in concordance with previous findings. 24, 39 We therefore argue that the CpG component was essential for the induction of the IFN-g response, something that is strengthened by the switch in antibody isotype from a Th2-type response towards a more balanced Th1/Th2-like response. 33, [40] [41] [42] In conclusion, we had developed a gene-based immunization strategy capable of strongly enhancing humoral immune responses to the HIV-1 envelope through rGM-CSF mediated immune enhancement in mice. Moreover, multi-subtype immunization increased the response frequency and broadened antibody neutralization and peptide reactivity. In clinical protocols, genetic immunization has been moderately successful. [43] [44] [45] Therefore, optimization of preclinical protocols is crucial for the future success of the DNA vaccine field. A similar DNA priming regimen may increase the potency and breadth of anti-HIV responses needed for an HIV vaccine to be effective in humans. Ultimately, phase I clinical trials with the HIV-1 envelope gene and rGM-CSF as a molecular adjuvant in healthy volunteers will show if the working hypothesis that the envelope DNA immunogen can be adjuvanted by GM-CSF also holds true in man. Such trials are in progress.
Materials and methods
Plasmids and immunizations
The gene-based immunogens pKCMVgp160 A, pKCMVgp160 B, pKCMVgp160 C and pKCMVrev have been described elsewhere. 29, 46 The gp160 B plasmid encodes the entire gp160 molecule, in which the furin cleavage site responsible for post-translational modification into gp120 and gp41 was deliberately modified by Induction of broadly neutralizing HIV-1 antibodies E Rollman et al site-directed mutagenesis, resulting in amino-acid changes R511S and A512M. The gp160 gene encoded by pKCMVgp160 B originates from a subtype B (LAI) virus, whereas the A and C plasmids encode chimeric molecules in which the V1-V5 region of the subtype B backbone has been replaced with corresponding fragments from WHO strains A92UG031 (HIV-1 subtype A) and 92BR025 (HIV-1 subtype C), respectively. All plasmids were grown in Escherichia coli and bacterial endotoxins were removed (QIAGEN Endofree mega plasmid kit, QIAGEN, Germany). Three immunization protocols (I-III) were used (Table 1) . Part I: Four groups of 10 C57Bl/6 mice (6-to 8-week-old female) were given 50 mg by the intramuscular (i.m.) route of either pKCMVgp160 A, pKCMVgp160 B or pKCMVgp160 C or a 25 þ 25 mg mixture of plasmids pKCMVgp160 A and C ( Table 1 , part I). Each envelope DNA dose was mixed with 50 mg pKCMVrev and dissolved in 50 ml H 2 O. An untreated group and a mock vector backbone (pKCMV)-immunized group were also included. Animals were killed 14 days after the last immunization. Part II: Two groups of C57Bl/6 mice were immunized i.m. by a single dose of 50 mg pKCMVgp160 B þ 50 mg pKCMVrev with or without 1 mg of murine rGM-CSF (R&D Systems, UK) ( Table 1 , part II). The rGM-CSF was mixed with the DNA in a total volume of 100 ml PBS. Animals were killed 30 days after the immunization. Part III: Two groups of C57Bl/6 mice were immunized twice i.m. with a total of 2 Â 100 mg of DNA (75 mg pKCMVgp160 B þ 25 mg pKCMVrev) ( Table 1 , part III). One group was given a mixture of 25 mg of plasmids pKCMVgp160 A, B and C together with 25 mg pKCMVrev. The total gp160 DNA dose in the multi-subtype group (75 mg) was the same as that of the subtype B-immunized group. The DNA was delivered in 50 ml H 2 O. rGM-CSF (1 mg) was administered to the site of immunization 15 min prior to vaccination, dissolved in 50 ml H 2 O. Booster immunizations were delivered at week 11 at the site of DNA immunization and consisted of 20 mg of rgp160 formulated in aluminum hydroxide (MicroGeneSys (now Protein Sciences), CT, USA) with or without 50 mg of the 1826 CpG-ODN motif (TCCATGACGTTCCT GACGTT, Cybergene, Sweden). 23 The B DNA-primed animals given a protein boost of rgp160 together with CpG-ODN is referred to as B1 group and the group given rgp160 only as B2. Blood was obtained 14 days after the second DNA immunization, followed by protein boosting and killing 14 days later.
Antibody IgG ELISA
ELISA was carried out essentially as described previously. 29 Briefly, ELISA plates (Nunc Maxisorp, Denmark) were coated with rgp160. The serum was diluted in 10-fold serial dilutions and reactive antibodies were detected with goat anti-mouse IgG antibodies conjugated to horseradish peroxidase (HRP) (Bio-Rad, CA, USA). Subclass IgG antibodies were detected using rabbit antimouse IgG1 and IgG2a antibodies (Sigma-Aldrich, Sweden) followed by a goat anti-rabbit HRP antibody (DAKO PO449, Denmark). Plates were developed with O-phenylene diamine and the OD was read at 490 nm. Two times the mean OD of the naïve sera was used as cutoff for a positive response. The anti-envelope serum IgG response was mapped by pooled sera using 48 individual peptides (15-mers with 5-mer overlap) representing amino acids 249-514 of gp120 HIV-1 subtype B. 47, 48 Two well-characterized gp41 antibody epitopes (NEQLLELDKWASLWN, amino acid 657-672; and KDQQLLGIWGCSGKLICT, amino acid 599-618) were also included. 49, 50 The cutoff for antibody mapping was calculated as the mean OD of negative sera plus three standard deviations.
HIV-1 neutralization assay
The HIV-1 neutralization assay was performed as described previously. 51 The viral isolates used for the neutralization were the WHO reference strains 92UG031 (subtype A) and 92BR025 (subtype C), the subtype B laboratory strains IIIB LAI (viral isolates from which the HIV-1 envelope gene fragments encoded by our DNA immunogens originate), the subtype B laboratory strain SF-2 and the primary subtype B isolate 6920. Briefly, the sera from mice responding with binding anti-envelope antibodies were pooled group wise, inactivated at 561C for 1 h to prevent complement-mediated neutralization. The sera were diluted in RPMI 1640 medium (Invitrogen, Scotland) in 96-well tissue culture plates (Nunc microwell plates, Nunc, Denmark). The sera and virus were mixed appropriately and incubated at 371C for 1 h followed by the addition of 100 000 human PBMCs activated by phytohemagglutinin. The cultures were incubated at 371C in 5% CO 2 over night, after which the cells were washed twice with RPMI 1640. After 6 days of culture, the presence of HIV-1 p24 antigen in the culture medium was measured. 52 The background in the p24 ELISA was determined for each plate and subtracted from all wells before the percentage neutralization was determined as [1À(mean p24 OD in the presence of test serum/mean p24 OD in the absence of test serum)] Â 100.
Lymphocyte proliferation and cytokine production
The lymphocyte proliferation was performed essentially as described earlier. 29 Splenocytes (400 000 per well) were cocultured with antigen (0.1 mg rgp160 per well) for 3 days before H 3 þ -labeled thymidine was added to each well and incubated for 16 h. The cells were harvested and counted in a b-counter (Wallac 1450, Finland). After 72 h, interferon-g and IL-4 were determined in the culture supernatants by ELISA in accordance with the manufacturer's instructions (R&D Systems, UK). Cryopreserved splenocytes were thawed, pooled group wise and cultured over night in 10% FCS-RPMI. These cells were used for the analysis of subtype crossreactivity: Two different peptide pools (50 peptides per pool, 15-mers with 8-mer overlap, at 1 mg/peptide/well), corresponding to the subtype variable regions (V1-V5, aa 120-477) of the subtypes A and C viruses, were used to determine proliferation in response to matched A and C antigen. In the prime-boost schedule (part III), murine PBMCs were analyzed 6 weeks after the second immunization with DNA and rGM-CSF by IFN-g ELISpot. Spleen-derived lymphocytes were also analyzed 10 days after the boost with rgp160. Briefly, blood was pooled from each group in EDTA-containing tubes. The blood was centrifuged and the peripheral lymphocytes purified by Ficoll-Paque (Amersham Pharmacia Biotech, Sweden). Alternatively, splenocytes were isolated from mashed spleens by centrifugation at 1000 rpm for 
